UnitedHealth Group Incorporated (0R0O)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 410.99 |
|---|---|
| 52-week range | 255.98 – 461.00 |
| Return, 1 month / 3 months | +9.2% / −1.1% |
| Return, 1 year / 3 years | +15.6% / −16.4% |
| Trend | Uptrend |
| RSI (14) | 59 |
| Volatility (1 year) | 35.4% |
| Worst drawdown (1 year) | -26.9% |
| Average daily value traded | 1.70M USD |
| Dividend yield | 2.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UnitedHealth Group Incorporated is a healthcare company based in the United States. Through its health benefits business it provides medical insurance plans to individuals, employers and government programmes, and through its health services business it offers pharmacy benefits management, healthcare data and analytics, and clinical care services. Its customers include employers, individuals, and public healthcare programmes, and it operates across the American healthcare system.
UnitedHealth Group Incorporated trades under the code 0R0O on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UnitedHealth Group Incorporated (0R0O) trades on the London Stock Exchange in UK. It last closed at USD 410.99 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,082 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 15.6% and over the last three months it fell 1.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.2% | ||
| From 52-week high | -5.6% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.1% | ||
| 6-month return | 17.5% | ||
| 12-month return, skipping the last month | 5.9% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.9% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.70M USD | ||
| Zero-volume days | 20.0% | ||
| Income | 61 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.2% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +9.2% |
| 3 months | −1.1% |
| 6 months | +17.5% |
| 1 year | +15.6% |
| 3 years | −16.4% |
| 5 years | −0.8% |
Signals
| 50-day / 200-day average | 388.86 / 359.96 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Sep 2026 | USD 2.3200 |
| 15 Jun 2026 | USD 2.3200 |
| 9 Mar 2026 | USD 2.2100 |
| 8 Dec 2025 | USD 2.2100 |
| 15 Sep 2025 | USD 2.2100 |
| 16 Jun 2025 | USD 2.2100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.